drugset / Trial / NCT01365936

hMG or Recombinant FSH on OHSS Prevention in PCOS Patients Undergoing IVF

NCT01365936

RandomizedParallel-groupOpen-labelTreatment

Summary

There have been some controversies regarding the use of preparations with LH activity in patients with polycystic ovary syndrome (PCOS) who have high endogenous LH activity. In this research we aimed to compare urinary menotrophin versus recombinant FSH (rFSH) with respect to the prevention of OHSS

Timeline

Start
2008-01
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Gonal-f Protein / enzyme biologic 150 iu
Comparator human chorionic gonadotropin Protein / enzyme biologic 150 iu